160 related articles for article (PubMed ID: 24411921)
1. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
Leuk Res; 2014 Mar; 38(3):329-33. PubMed ID: 24411921
[TBL] [Abstract][Full Text] [Related]
2. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE
Blood; 2007 Feb; 109(4):1387-94. PubMed ID: 17082323
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Karp JE; Smith BD; Gojo I; Lancet JE; Greer J; Klein M; Morris L; Levis MJ; Gore SD; Wright JJ; Garrett-Mayer E
Clin Cancer Res; 2008 May; 14(10):3077-82. PubMed ID: 18483374
[TBL] [Abstract][Full Text] [Related]
5. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
[TBL] [Abstract][Full Text] [Related]
7. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
[TBL] [Abstract][Full Text] [Related]
8. Tipifarnib in acute myeloid leukemia.
Burnett AK; Kell J
Drugs Today (Barc); 2007 Nov; 43(11):795-800. PubMed ID: 18174965
[TBL] [Abstract][Full Text] [Related]
9. Tipifarnib: farnesyl transferase inhibition at a crossroads.
Mesa RA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
[TBL] [Abstract][Full Text] [Related]
10. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
van der Weide K; de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
Clin Cancer Res; 2009 May; 15(9):3076-83. PubMed ID: 19383813
[TBL] [Abstract][Full Text] [Related]
11. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Epling-Burnette PK; Loughran TP
Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL; Martinelli G; Jedrzejczak WW; Brandwein JM; Bordessoule D; Masszi T; Ossenkoppele GJ; Alexeeva JA; Beutel G; Maertens J; Vidriales MB; Dombret H; Thomas X; Burnett AK; Robak T; Khuageva NK; Golenkov AK; Tothova E; Mollgard L; Park YC; Bessems A; De Porre P; Howes AJ;
Blood; 2009 Aug; 114(6):1166-73. PubMed ID: 19470696
[TBL] [Abstract][Full Text] [Related]
13. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Luger SM; Wang VX; Rowe JM; Litzow MR; Paietta E; Ketterling RP; Lazarus H; Rybka WB; Craig MD; Karp J; Cooper BW; Makary AZ; Kaminer LS; Appelbaum FR; Larson RA; Tallman MS
Leuk Res; 2021 Dec; 111():106736. PubMed ID: 34773794
[TBL] [Abstract][Full Text] [Related]
14. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Burnett AK; Russell NH; Culligan D; Cavanagh J; Kell J; Wheatley K; Virchis A; Hills RK; Milligan D;
Br J Haematol; 2012 Aug; 158(4):519-22. PubMed ID: 22639959
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Brandwein JM; Leber BF; Howson-Jan K; Schimmer AD; Schuh AC; Gupta V; Yee KW; Wright J; Moore M; MacAlpine K; Minden MD;
Leukemia; 2009 Apr; 23(4):631-4. PubMed ID: 19092853
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Sparano JA; Moulder S; Kazi A; Vahdat L; Li T; Pellegrino C; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Sebti SM
J Clin Oncol; 2006 Jul; 24(19):3013-8. PubMed ID: 16769985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
